Kane Biotech Inc.

OTCPK:KNBI.F Stock Report

Market Cap: US$4.3m

Kane Biotech Management

Management criteria checks 4/4

Kane Biotech's CEO is Rob Huizinga, appointed in Apr 2025, has a tenure of 1.25 years. total yearly compensation is CA$130.32K, comprised of 97.4% salary and 2.6% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $61.96K. The average tenure of the management team and the board of directors is 4.3 years and 4.5 years respectively.

Key information

Rob Huizinga

Chief executive officer

CA$130.3k

Total compensation

CEO salary percentage97.43%
CEO tenure1.3yrs
CEO ownership1.4%
Management average tenure4.3yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Huizinga's remuneration changed compared to Kane Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-CA$2m

Dec 31 2025CA$130kCA$127k

-CA$3m

Sep 30 2025n/an/a

-CA$2m

Jun 30 2025n/an/a

-CA$2m

Mar 31 2025n/an/a

-CA$3m

Dec 31 2024CA$239kCA$106k

-CA$3m

Compensation vs Market: Rob's total compensation ($USD91.80K) is below average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Huizinga (61 yo)

1.3yrs
Tenure
CA$130,320
Compensation

Dr. Robert B. Huizinga, also known as Rob, Ph.D. RN NNC, M.Sc. (Epi), CNeph(C), served as an Executive Vice President of Research at Aurinia Pharmaceuticals Inc. since June 2020 until October 31, 2022. He...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Huizinga
Interim CEO1.3yrsCA$130.32k1.43%
$ 62.0k
Ray Dupuis
Chief Financial Officer8.8yrsCA$190.56k0.53%
$ 22.9k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board4.3yrsno datano data
Lorne Gorber
Investor Relationsno datano datano data
4.3yrs
Average Tenure

Experienced Management: KNBI.F's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Huizinga
Interim CEO7.8yrsCA$130.32k1.43%
$ 62.0k
Gregory Schultz
Chief Scientific Officer & Member of Scientific Advisory Board4.5yrsno datano data
Shameze Rampertab
Independent Director1.1yrsCA$4.98kno data
Philip Renaud
Chairman15.8yrsCA$10.17k34.33%
$ 1.5m
Rashieda Gluck
Member of Scientific Advisory Board7.8yrsCA$13.30kno data
David Kideckel
Independent Director1.1yrsCA$4.64kno data
Gordon Guay
Chairman of Scientific Advisory Board7.8yrsno datano data
Anne Greven
Independent Director1.1yrsCA$4.98kno data
John Coleman
Lead Independent Director2.7yrsCA$57.73kno data
4.5yrs
Average Tenure
60yo
Average Age

Experienced Board: KNBI.F's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 21:22
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.